Korro Bio (KRRO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, to be held virtually for stockholders of record as of April 13, 2026.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request by May 29, 2026.
Voting matters and shareholder proposals
Election of two Class I directors, Nessan Bermingham and Rachel Meyers, each for a three-year term expiring at the 2029 annual meeting.
Non-binding advisory vote on the compensation of named executive officers (say-on-pay).
Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Provision for transaction of any other business that may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting for the nominated directors and for all proposals presented.
Latest events from Korro Bio
- Virtual meeting to vote on directors, say-on-pay, auditor, and review governance and compensation.KRRO
Proxy filing16 Apr 2026 - KRRO-121 advances as a first-in-class RNA editing therapy for hyperammonemia, with key milestones ahead.KRRO
Corporate presentation23 Mar 2026 - RNA editing biotech registers 7.65M shares for resale after $85M private placement.KRRO
Registration Filing13 Mar 2026 - KRRO-121 advanced, AATD program pivoted, and $85M financing extended cash runway into 2028.KRRO
Q4 202512 Mar 2026 - First-in-class RNA editing therapy for ammonia disorders targets late 2026 clinical trials.KRRO
Analyst Day 20262 Feb 2026 - Lead RNA editing therapy for alpha-1 antitrypsin deficiency nears clinical stage with strong preclinical data.KRRO
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - RNA editing platform advances lead therapy for alpha-1 antitrypsin deficiency toward clinical trials.KRRO
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - RNA editing platform advances toward clinical trials and expands via Novo Nordisk partnership.KRRO
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - RNA editing platform advances with lead program and Novo Nordisk partnership, runway into 2026.KRRO
Chardan's 8th Annual Genetic Medicines Conference20 Jan 2026